Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2019-06-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于控股股东股权解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the release of pledged shares by its controlling shareholder. It details the number of shares released from pledge, the dates of previous pledges and releases, and the current shareholding and pledge status. There are no financial statements, earnings data, or management discussions. The document is a formal disclosure about share pledge status, which fits the category of Regulatory Filings (RNS) as it is a regulatory announcement about shareholding and pledge status that does not fit into more specific categories like Major Shareholding Notification (MRQ) or Transaction in Own Shares (POS). The document length is short (1642 characters), and it is an announcement rather than a report or detailed financial document.
2019-06-20 Chinese
关于与广州高新区投资集团有限公司签署战略合作框架协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a strategic cooperation framework agreement between Kangzhi Pharmaceutical Co., Ltd. and Guangzhou High-tech Zone Investment Group Co., Ltd. It details the nature of the agreement, the parties involved, the cooperation goals, and the impact on the company. The document explicitly states that the agreement is an intention framework without specific financial commitments or resource transfers, and it does not constitute a major asset restructuring. It is a formal disclosure to shareholders and the market about a strategic partnership intention, not a financial report, earnings release, or management discussion. The document length is 3418 characters, which is relatively short and consistent with an announcement rather than a full report. There is no financial data, no detailed financial statements, no audit information, no voting results, no executive changes, and no legal proceedings. Therefore, the document fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2019-06-20 Chinese
关于控股股东协议转让部分公司股份暨权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding a significant change in shareholding involving a controlling shareholder transferring part of its shares to a new strategic investor. It includes specifics about the share transfer agreement, parties involved, shareholding percentages before and after the transaction, and compliance with relevant laws and regulations. The document is not a full financial report, earnings release, or management discussion but rather a formal notification of a major shareholding change. It references the issuance of a "简式权益变动报告书" (Simplified Equity Change Report) and details the share transfer agreement and related disclosures. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document length and content confirm it is not a brief announcement or a report publication notice but a substantive disclosure of shareholding changes.
2019-06-20 Chinese
简式权益变动报告书（二）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书（二）" which translates to a "Simplified Equity Change Report (No. 2)". It details a shareholding change involving Guangzhou High-tech Zone Investment Group Co., Ltd. acquiring 10% of the shares of Kangzhi Pharmaceutical Co., Ltd. through an agreement transfer. The document includes detailed information about the parties involved, the share transfer agreement, the purpose of the equity change, and related legal and regulatory compliance statements. It is a formal report on a change in significant share ownership, specifically a shareholding notification due to crossing a threshold (10%). There is no indication that this is an annual report, earnings release, or any other type of financial or management report. The document is not a mere announcement of a report publication but a substantive report itself. Therefore, the most appropriate classification is "Major Shareholding Notification" (MRQ).
2019-06-20 Chinese
简式权益变动报告书（一）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书（一）" which translates to a "Simplified Equity Change Report (No. 1)". It details a significant change in shareholding by the information disclosure obligor, 海南宏氏投资有限公司, involving a reduction of shares through an agreement transfer. The document includes detailed information about the shareholder, the shareholding percentages before and after the transaction, the purpose of the equity change, the transfer agreement terms, and legal compliance statements. It is a formal report disclosing a change in major shareholding stakes, consistent with notifications required when a shareholder's equity interest crosses certain thresholds or changes significantly. There is no indication that this is an annual report, earnings release, or any other financial report type. It is not a proxy solicitation, AGM material, or management change announcement. The document is comprehensive and not a mere announcement of a report publication. Therefore, the most appropriate classification is "Major Shareholding Notification" (MRQ).
2019-06-20 Chinese
2018年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and validity of the 2018 Annual General Meeting (AGM) of 康芝药业股份有限公司. It details the procedures of the AGM, including the convening, attendance, agenda items, and voting results. The document does not contain the actual annual report or financial statements but rather confirms the legality of the AGM process and its resolutions. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA) because it reports on the official voting outcomes and validates the meeting procedures and resolutions. The document length (6251 characters) and content support that it is not a brief announcement but a detailed legal opinion on the AGM proceedings and voting results, fitting the DVA category rather than a simple announcement or the full annual report itself.
2019-06-17 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.